May 1, 2012

ANAPTYSBIO ANNOUNCES ANTIBODY DISCOVERY PARTNERSHIP WITH GILEAD SCIENCES

SHM-XEL platform to generate novel therapeutic antibodies

 
SAN DIEGO, Calif. – AnaptysBio, Inc., a privately-held therapeutic antibody company, today announced an antibody discovery partnership with Gilead Sciences, Inc. to develop novel antibody therapeutics.

Under this partnership, antibodies generated by AnaptysBio using its proprietary SHM-XEL platform will be transferred to Gilead for worldwide development and commercialization. Gilead has paid an upfront fee upon signature of the partnership and will continue to provide research funding to AnaptysBio through the antibody generation process. AnaptysBio is due to receive development milestone payments from Gilead, as well as royalties upon sales of each product derived from the partnership.

“Our pharma partners continue to recognize the unique advantages of AnaptysBio’s SHM-XEL antibody generation platform,” said Hamza Suria, AnaptysBio’s president and chief executive officer. “We look forward to working with Gilead in the discovery of novel antibodies for the treatment of human disease.”